報價延遲最少15分鐘:2026/04/25 22:03 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.28/--
|
|
企業價值
130.53M
|
| 資產負債 |
|
每股賬面淨值
4.60
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
16.12M
|
|
每股收益
0.26
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. |
